Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - capsule, modified release - excipient ingredients: macrogol 6000; gelatin; purified talc; titanium dioxide; magnesium stearate; hydrogenated vegetable oil; sodium lauryl sulfate; indigo carmine; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - capsule, modified release - excipient ingredients: iron oxide red; sodium lauryl sulfate; indigo carmine; magnesium stearate; titanium dioxide; purified talc; macrogol 6000; iron oxide yellow; gelatin; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 90 mg - capsule, modified release - excipient ingredients: purified talc; iron oxide red; titanium dioxide; magnesium stearate; sodium lauryl sulfate; iron oxide black; macrogol 6000; erythrosine; hydrogenated vegetable oil; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 120 mg - capsule, modified release - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; purified talc; titanium dioxide; magnesium stearate; gelatin; indigo carmine; iron oxide black; macrogol 6000; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 5 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose; cetostearyl alcohol; purified talc; hyetellose; titanium dioxide; hypromellose; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose; povidone; pregelatinised maize starch; magnesium stearate; purified talc; titanium dioxide; brilliant blue fcf; hypromellose; macrogol 400 - treatment of chronic severe pain of cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - tablet, modified release - excipient ingredients: hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; indigo carmine aluminium lake; hypromellose; iron oxide yellow; iron oxide black; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; erythrosine; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; indigo carmine; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 80 mg; naloxone hydrochloride dihydrate, quantity: 43.6 mg (equivalent: naloxone hydrochloride?, qty 40 mg) - tablet, modified release - excipient ingredients: ethylcellulose; stearyl alcohol; lactose monohydrate; purified talc; magnesium stearate; povidone; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.